Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

FDA Approves Abiraterone for High-Risk Prostate Cancer

February 8th 2018

The FDA has approved abiraterone acetate in combination with prednisone and androgen deprivation therapy for high-risk patients with metastatic hormone-naïve prostate cancer or newly-diagnosed metastatic hormone-sensitive prostate cancer.

Dr. Morgan on Combinations With PARP Inhibitors in Prostate Cancer

February 7th 2018

Alicia Morgan, MD, Mather Hospital, discusses combinations with PARP inhibitors in prostate cancer.

Docetaxel Adds to QALY in Advanced Prostate Disease

February 6th 2018

The addition of docetaxel (Taxotere) to frontline long-term hormone therapy for advanced prostate cancer improved quality of life and reduced the need for subsequent therapy, contributing to lower overall costs in the nonmetastatic setting.

Apalutamide Delays Metastasis by Over 2 Years in Prostate Cancer

February 6th 2018

Apalutamide (ARN-509) reduced the risk of metastasis or death by 72% in patients with nonmetastatic castration-resistant prostate cancer, according to findings from the phase III SPARTAN trial.

Enzalutamide More Than Doubles MFS for Nonmetastatic CRPC

February 6th 2018

Treatment with the combination of enzalutamide and androgen deprivation therapy reduced the risk of metastases or death by 71% compared with ADT alone in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Wise on AR-Directed Therapy for Prostate Cancer

February 3rd 2018

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone's Perlmutter Cancer Center, discusses advancements with androgen receptor (AR)-directed therapy for patients with prostate cancer.

Dr. Taneja Discusses Multiparametric MRI in Prostate Cancer

February 3rd 2018

Samir Taneja, MD, James M. Neissa and Janet Riha Neissa professor of urologic oncology, vice chair, Department of Urology, professor, Department of Radiology, co-director, Smilow Comprehensive Prostate Cancer Center, director, Urologic Oncology, Genito-Urologic program leader, NYU Langone’s Perlmutter Cancer Center, discusses multiparametric MRI in prostate cancer.

Update Sustains OS Benefit of Chemohormonal Therapy in High-Volume Prostate Cancer

February 2nd 2018

Adding docetaxel to androgen-deprivation therapy improved overall survival by nearly 17 months in men with high-volume metastatic hormone-sensitive prostate cancer.

Dr. Mason on Treatment Decisions Following 10-Year PROTECT Data in Prostate Cancer

February 1st 2018

Malcolm Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses how to determine a treatment strategy for patients with prostate cancer following the 10-year PROTECT study data.

Expert Highlights Significance of MRI-Guided Prostate Biopsies

February 1st 2018

Samir Taneja, MD, discusses his research on MRI-guided prostate biopsies and other modalities in development.

Dr. Morgan Discusses the Impact of PARP Inhibitors in Prostate Cancer

February 1st 2018

Alicia Morgan, MD, Mather Hospital, discusses the impact of PARP inhibitors in prostate cancer.

Dr. Oh on Abiraterone Versus Docetaxel in Prostate Cancer

January 31st 2018

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the abiraterone acetate (Zytiga) versus docetaxel for patients with prostate cancer.

Dr. Wise on the Development of Precision Medicine in Prostate Cancer

January 30th 2018

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses ongoing trials at NYU that are investigating precision oncology hypotheses.

Expert Shares Insight on Immunotherapy, Emerging Strategies in Prostate Cancer

January 30th 2018

David R. Wise, MD, PhD, discusses the promise for immunotherapy and other emerging approaches in the field of prostate cancer.

Screening Continues to Evolve in Prostate Cancer

January 30th 2018

Marc A. Bjurlin, DO, discusses ongoing efforts to optimize prostate cancer screening.

Dr. Taneja Discusses Imaging Techniques Used to Detect Metastatic Prostate Cancer

January 27th 2018

Differentiating Molecular Risk Assessments of Prostate Cancer

January 26th 2018

Marc A. Bjurlin, DO, clinical assistant professor, Department of Urology, NYU Langone Medical Center, discusses differentiating molecular risk assessments for patients with prostate cancer.

10-Year PROTECT Data Underscore Significance of Precision Medicine in Prostate Cancer

January 22nd 2018

Malcolm Mason, MD, discusses the significance of the 10-year follow-up of the PROTECT study for patients with prostate cancer and what it means for the field going forward.

CTCs Better Overall Survival Predictors Than PSA in mCRPC

January 21st 2018

An analysis of results from 5 clinical trials showed that circulating tumor cell (CTC) conversion and CTC value ≥ 1 at baseline were superior predictors of overall survival than PSA in men with metastatic castration-resistant prostate cancer.

Dr. Morgan on Enrolling Patients With Prostate Cancer onto Clinical Trials

January 20th 2018

Alicia Morgan, MD, Mather Hospital, discusses enrolling patients with prostate cancer onto clinical trials investigating PARP inhibitors.